| Previous Close | 4.40 |
| Open | 4.40 |
| Bid | 4.45 x 11300 |
| Ask | 4.50 x 11900 |
| Day's Range | 4.35 - 4.50 |
| 52 Week Range | 3.85 - 6.39 |
| Volume | 320,934 |
| Avg. Volume | 645,298 |
| Market Cap | 369.35M |
| Beta | 2.19 |
| PE Ratio (TTM) | -11.41 |
| EPS (TTM) | -0.39 |
| Earnings Date | Aug 15, 2017 - Aug 21, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 |
- Zacks•yesterday
New Strong Sell Stocks for July 24th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
CNW Group•5 days agoNew Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
New Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
- PR Newswire•5 days ago
New Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
SUNNYVALE, Calif., July 20, 2017 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that a prospective study conducted at 14 French centers showed the clinical benefits of intensity-modulated radiation therapy (IMRT) delivered using the TomoTherapy® System over volumetric modulated arc therapy with RapidArc radiotherapy technology for patients with head and neck cancer. At 18 months, the local control rate and cancer-specific survival rate were significantly better in the TomoTherapy patient group than in the RapidArc group.
